CY1115601T1 - Συζευγματα που περιλαμβανουν νανοσωματιδια επικαλυμμενα με λευκοχρυσουχες ενωσεις - Google Patents

Συζευγματα που περιλαμβανουν νανοσωματιδια επικαλυμμενα με λευκοχρυσουχες ενωσεις

Info

Publication number
CY1115601T1
CY1115601T1 CY20141100802T CY141100802T CY1115601T1 CY 1115601 T1 CY1115601 T1 CY 1115601T1 CY 20141100802 T CY20141100802 T CY 20141100802T CY 141100802 T CY141100802 T CY 141100802T CY 1115601 T1 CY1115601 T1 CY 1115601T1
Authority
CY
Cyprus
Prior art keywords
formula
conjugates
nanosomatic
white
coated
Prior art date
Application number
CY20141100802T
Other languages
Greek (el)
English (en)
Inventor
Puntes Víctor Franco
Puente Fernando Domínguez
Martínez Francisco Manuel Romero
Rubio Óscar Gallego
Original Assignee
Fundació Privada Institut Català De Nanotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institut Català De Nanotecnologia filed Critical Fundació Privada Institut Català De Nanotecnologia
Publication of CY1115601T1 publication Critical patent/CY1115601T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Powder Metallurgy (AREA)
CY20141100802T 2008-12-16 2014-10-03 Συζευγματα που περιλαμβανουν νανοσωματιδια επικαλυμμενα με λευκοχρυσουχες ενωσεις CY1115601T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171870 2008-12-16
EP09768395.7A EP2379114B1 (en) 2008-12-16 2009-12-15 Conjugates comprising nanoparticles coated with platinum containing compounds

Publications (1)

Publication Number Publication Date
CY1115601T1 true CY1115601T1 (el) 2017-01-04

Family

ID=40568646

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100802T CY1115601T1 (el) 2008-12-16 2014-10-03 Συζευγματα που περιλαμβανουν νανοσωματιδια επικαλυμμενα με λευκοχρυσουχες ενωσεις

Country Status (13)

Country Link
US (1) US9023370B2 (enExample)
EP (1) EP2379114B1 (enExample)
JP (1) JP5873719B2 (enExample)
CA (1) CA2745972C (enExample)
CY (1) CY1115601T1 (enExample)
DK (1) DK2379114T3 (enExample)
ES (1) ES2505890T3 (enExample)
HR (1) HRP20140804T1 (enExample)
IL (1) IL213408A (enExample)
PL (1) PL2379114T3 (enExample)
PT (1) PT2379114E (enExample)
SI (1) SI2379114T1 (enExample)
WO (1) WO2010069941A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0909435D0 (en) * 2009-06-02 2009-07-15 Univ Strathclyde Nanoparticle for biomolecule delivery
ES2392528B1 (es) * 2010-12-28 2013-10-21 Endor Nanotechnologies, S.L. Sistema de liberación de agente terapéutico, composiciones farmacéuticas que lo contienen, su preparación y su uso médico.
ITRM20130138A1 (it) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
JP6316011B2 (ja) * 2014-02-04 2018-04-25 国立大学法人滋賀医科大学 抗癌剤が担持されたナノ粒子
JP7018191B2 (ja) * 2016-01-29 2022-02-10 国立大学法人北海道大学 細胞内物質移送システムおよびその利用
PL236093B1 (pl) 2017-07-04 2020-11-30 Dominika Szczepaniak Rozpuszczalne w wodzie kompleksy złota (III), sposób wytwarzania rozpuszczalnych w wodzie kompleksów złota (III) i ich zastosowanie
WO2020144222A1 (en) 2019-01-08 2020-07-16 Nanonica S.A. Conjugates comprising nanoparticles coated with platinum derivatives through sulfonyl or phosphonyl-containing linkers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851932B (enExample) 1984-08-14 1985-12-13 Engelhard Corp
JP2866554B2 (ja) 1992-08-25 1999-03-08 松下電器産業株式会社 情報記録媒体とその製造方法及び情報記録媒体の使用方法
AU2003273272A1 (en) 2002-06-03 2003-12-19 Alinis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
WO2006037081A2 (en) * 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
US7601331B2 (en) 2004-11-10 2009-10-13 National University Of Singapore NIR-sensitive nanoparticle
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US8785505B2 (en) * 2005-10-28 2014-07-22 The Regents Of The University Of California Toxicology and cellular effect of manufactured nanomaterials

Also Published As

Publication number Publication date
IL213408A0 (en) 2011-07-31
IL213408A (en) 2017-06-29
HRP20140804T1 (hr) 2014-11-07
PL2379114T3 (pl) 2014-12-31
EP2379114B1 (en) 2014-07-09
US20110262500A1 (en) 2011-10-27
US9023370B2 (en) 2015-05-05
PT2379114E (pt) 2014-10-06
CA2745972A1 (en) 2010-06-24
JP5873719B2 (ja) 2016-03-01
CA2745972C (en) 2016-11-01
JP2012512149A (ja) 2012-05-31
WO2010069941A1 (en) 2010-06-24
ES2505890T3 (es) 2014-10-10
DK2379114T3 (da) 2014-09-29
SI2379114T1 (sl) 2014-11-28
EP2379114A1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CY1115601T1 (el) Συζευγματα που περιλαμβανουν νανοσωματιδια επικαλυμμενα με λευκοχρυσουχες ενωσεις
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
MX2021015221A (es) Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
CO6290714A2 (es) Compuestos organicos
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
MX2012013274A (es) Novedosos derivados de la pirimidina.
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
EA200971116A1 (ru) Способ желатинизации фиброина шелка с применением обработки ультразвуком
TN2010000167A1 (en) Organic compounds
MX2010003368A (es) Derivados de imidazol.
EP4295841A3 (en) Sulfur (vi) fluoride compounds and their use in click-reaction
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
PH12014500791A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EA200901529A1 (ru) Производные арилоазол-2-илцианоэтиламина, способ их получения и способ их применения
UY30493A1 (es) Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
MX345440B (es) Metodo para modificar quimicamente la region interna del tallo del cabello.
NO20074414L (no) 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft
PE20130254A1 (es) Factor viii conjugado para coagulacion de la sangre
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
ATE471933T1 (de) Neue imidazolderivate, ihre herstellung und ihre verwendung als medizin
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
NZ594186A (en) Indole derivatives as anticancer agents